Document:

<PAGE>

                                                                   EXHIBIT 10.14

Confidential

                       RESEARCH AND DEVELOPMENT AGREEMENT

BETWEEN

Chemokine Therapeutics Corp.
2386 East Mall
Suite 208
Vancouver, B.C.
V6T 1Z3
Canada

AND

Procter & Gamble Pharmaceuticals, Inc.
8700 Mason-Montgomery Road
Mason,
OH 45040-9462
USA

          CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN REDACTED
          PROVISIONS OF THIS AGREEMENT. THE REDACTED PROVISIONS ARE INDICATED BY
          THREE ASTERISKS ENCLOSED BY BRACKETS AND UNDERLINED. THE CONFIDENTIAL
          PORTIONS HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
          COMMISSION.

WHEREAS:

      1. Chemokine Therapeutics, Corp. (hereinafter "CTC") has:

            a.    Proprietary rights and know-how to certain chemokine analogs,
                  including chemokine stromal cell derived factor 1 (SDF-1) and
                  chemokine interleukin 8 (IL-8) analogs as well as other
                  potential chemokine products (agonists and antagonists) that
                  appear to have efficacy in a range of areas including, but not
                  limited to the development of cardiac muscle and vascular
                  tissues, collectively categorized as neovascularization.

            b.    Strong molecular creation, development, and manufacturing
                  capabilities in the field of peptides and the design of
                  chemokine-based products.

            c.    An affiliated subsidiary company called Globe Laboratories
                  Inc. ("Globe Laboratories") which is involved in peptide and
                  protein manufacturing.

      2. Procter & Gamble Pharmaceuticals (hereinafter "PGP") has:

            a.    A research and development program directed toward therapeutic
                  applications for vascular and cardiovascular disease
                  management.

            b.    Capabilities in testing and validation of new therapeutic
                  approaches for vascular and cardiovascular disease.

            c.    A desire to evaluate analogs of chemokine stromal cell derived
                  factor 1 (SDF-1 analogs).

            d.    An interest in requesting CTC to create new mimetics of yet to
                  be determined chemokine molecules.

CTC-PGP Research Agreement
29 June 2004

                                       1
<PAGE>

Confidential

NOW THEREFORE, CTC and PGP in consideration of the mutual covenants contained
herein agree as follows:

1   DEFINITIONS IN THIS AGREEMENT

      1.1   "Agreement" shall mean this Agreement, the recitals herein and the
            Appendices A, B, and C hereto.

      1.2   "Collaboration Compound" shall mean a non-CTC Compound and not
            covered in any CTC patents which is discovered or developed jointly
            during the Study or Reporting periods of this Agreement and jointly
            owned by CTC and PGP equally.

      1.3   "Confidential Information" shall mean Information pursuant to
            Section 1.9, which the disclosing Party indicates is confidential.
            Confidential Information shall be so marked when disclosed in
            writing or shall be reduced to writing and be so marked within
            thirty (30) days after disclosure if disclosed by any means other
            than writing.

      1.4   "CTC Affiliated Company" shall be Globe Laboratories Inc.

      1.5   "CTC Compounds" shall mean the compounds described in Appendix A
            hereto.

      1.6   "Data" shall mean the measurements, results, and information whether
            electronic or hardcopy, developed by PGP in the execution of the
            Study Plans and solely related to the CTC Compounds.

      1.7   "Effective Date" shall be the last date of execution of this
            Agreement.

      1.8   "Field" shall mean the development of therapeutic drugs for vascular
            and cardiovascular disease, and cardiac muscle regeneration
            including neovascularization.

      1.9   "Information" shall mean any information, data, or materials, in
            whatever form disclosed by a Party to the other Party under this
            Agreement including without limitation all scientific, pre-clinical,
            clinical, regulatory, manufacturing, marketing, financial and
            commercial information or data, non-limiting examples of which
            include: amino acid or nucleic acid sequences, plasmids, vectors,
            expression systems, cells, cell lines, antibodies, biological
            substances, and constituents, progeny, mutants, derivatives or
            replications thereof or there from, together with all reagents,
            chemical compounds or other material, data, information about
            methods of operation, processes, formulations, technical
            information, equipment or apparatus, memoranda or reports, know-how,
            clinical reports, patent prosecution status and strategy, business
            plans, cost, sales and research or marketing developments.

CTC-PGP Research Agreement
29 June 2004

                                       2
<PAGE>

Confidential

      1.10  "Option" shall mean the right to negotiate an exclusive license, as
            per Appendix C of this Agreement, on CTC Compounds for further
            development in the Field.

      1.11  "Option Period" shall mean the period of sixty (60) days after the
            thirty (30) days Reporting Period.

      1.12  "Party" or "Parties" shall mean CTC or PGP individually or CTC and
            PGP jointly, as the context requires.

      1.13  "Report" shall mean the report to be delivered by PGP to CTC thirty
            (30) days after the Study Period.

      1.14  "Reporting Period" shall mean thirty (30) days after the Study
            Period.

      1.15  "Services" shall be the work done by PGP during the Study Period of
            this Agreement.

      1.16  "Study Period" shall be nine (9) months.

      1.17  "Study Plans" shall mean the individual plan or the two plans
            together mutually agreed upon by the Parties for the evaluation of
            CTC Compounds. The Study Plans are attached as Appendix B.

2   EXCLUSIVE RESEARCH PROGRAM

      2.1   CTC grants to PGP an exclusive research opportunity to evaluate the
            CTC Compounds in the Field, in Ex vivo and In vivo evaluations
            conducted in accordance with the Study Plans. This exclusive
            research opportunity shall comprise two distinct periods, as
            follows:

            2.1.1 Study Period:

                  PGP shall have an exclusive opportunity to evaluate any or all
                  of the CTC Compounds in Ex vivo and In vivo models of
                  cardiovascular disease in accordance with the Study Plans. The
                  Study Period will commence on the Effective Date, but the
                  commencement of the Study Period will be extended on a
                  day-for-day basis until CTC provides to PGP a sufficient
                  amount (as contemplated in the Study Plans and Paragraph 2.3
                  of this Agreement) of all of the CTC Compounds to enable PGP
                  to commence the evaluation.

            2.1.2 Reporting period:

                  Upon completion by PGP of the Study Period conducted in
                  accordance with the Study Plans, PGP shall prepare, and
                  deliver to CTC within thirty (30) days, a detailed Report on
                  the results of the evaluations conducted in accordance with
                  the Study Plans,

CTC-PGP Research Agreement
29 June 2004

                                       3
<PAGE>

Confidential

                  including all data, analysis, and conclusions drawn by PGP in
                  relation to such evaluations.

      2.2   In consideration of the exclusive research opportunity granted to
            PGP by CTC, and in consideration of the exclusive option to license
            contemplated in Paragraph 3 of this Agreement, PGP shall pay to CTC
            or to the CTC Affiliated Company the following amounts:

            a)    the amount of two-hundred seventy five thousand ($275,000.00)
                  United States dollars within forty five (45) days of the
                  Effective Date of this Agreement and subject to Section 2.2
                  (c); and

            b)    an additional one hundred thousand ($100,000.00) United States
                  dollars at the beginning of any and all subsequent three (3)
                  month periods, subject to a request for extension of the Study
                  Period in writing by PGP; and

            c)    payments will be made by PGP within forty five (45) days of
                  receipt by the PGP Accounts Payable department of an invoice
                  from CTC, subject to registration of vendor data by CTC and
                  CTC Affiliated Company with PGP. Invoices must include the
                  purchase order number assigned by PGP, vendor registration
                  number and should be sent to Accounts Payable, Procter &
                  Gamble, P.O. Box 5555, Cincinnati, Ohio 45201-5555.

      2.3   To facilitate PGP's evaluation of the CTC Compounds during the Study
            Period, CTC shall provide CTC Compounds to PGP on the following
            terms:

            a)    During the Study Period, CTC shall provide to PGP up to ten
                  (10) milligrams (mg) of any or all of the CTC Compounds at no
                  charge for Ex vivo testing. CTC and PGP agree that a
                  sufficient amount of CTC Compounds to enable PGP to commence
                  the Ex vivo evaluation is no more than ten (10) milligrams
                  (mg) of each of the CTC Compounds. Additional quantities of
                  CTC Compounds for use in the Ex vivo evaluation shall be made
                  available by CTC to PGP upon request and payment to CTC of
                  CTC's manufacturing costs, plus labour calculated at one
                  hundred fifty ($150.00) United States dollars per hour.

            b)    During the Study Period, CTC shall provide to PGP up to two
                  hundred fifty (250) milligrams (mg) of any or all of the CTC
                  Compounds at no charge for In vivo testing. CTC and PGP agree
                  that a sufficient amount of CTC Compounds to enable PGP to
                  commence the In vivo evaluation is no more than two hundred
                  fifty (250) milligrams (mg) of each of the CTC Compounds.
                  Additional quantities of CTC Compounds for use in the In vivo
                  evaluation shall be made available by CTC to PGP upon request
                  and payment to CTC of CTC's manufacturing costs, plus labour
                  calculated at one

CTC-PGP Research Agreement
29 June 2004

                                       4
<PAGE>

Confidential

                  hundred fifty ($150.00) United States dollars per hour.

            c)    Upon conclusion of the exclusive research opportunity, PGP
                  shall return to CTC any unused quantities of CTC Compounds.

      2.4   CTC and PGP shall collaborate and share Confidential Information and
            Data during the Study and Reporting Periods of the exclusive
            research opportunity, as may be necessary to facilitate the
            execution and analysis of the Study Plans. Permitted uses and
            ownership of any Collaboration Compound or other jointly-developed
            intellectual property that may arise from any such collaboration
            during the Study and Reporting Periods of the exclusive research
            opportunity are dealt with in Paragraph 5 of this Agreement.

      2.5   For the purpose of this Agreement payments as per clauses 2.2 and
            2.3 should be paid to CTC Affiliated Company (Globe Laboratories)
            and future Milestones and Royalties as per Appendix C shall be paid
            to CTC.

3.  EXCLUSIVE OPTION TO LICENSE

      3.1   Upon conclusion of the exclusive research program, PGP shall have
            sixty (60) days ("Option Period"), calculated from the date of
            receipt by CTC of the Report contemplated in Paragraph 2.1.2 of this
            Agreement, within which to seek and conclude an exclusive license
            agreement with CTC relating to the further development and
            commercialization of one of the CTC Compounds. This time limit may
            be extended by a further sixty (60) days upon consent by CTC.

      3.2   If PGP does seek an exclusive license in relation to the further
            development and commercialization of any one of the CTC Compounds,
            CTC and PGP agree to use their best efforts to negotiate and
            conclude a license agreement that reflects the Heads of Agreement
            set out in "Appendix C". Separate exclusive license agreements will
            be required in relation to each CTC Compound if PGP seeks licenses
            in relation to the further development and commercialization of more
            than one of the CTC Compounds. The terms of the license agreement
            for additional compounds will be negotiated between CTC and PGP at
            the later stage.

      3.3   If PGP does not seek an exclusive license from CTC within the Option
            Period defined in Paragraph 3.1, then the Report contemplated in
            Paragraph 2.1.2 of this Agreement, the Data, and any Confidential
            Information both generated by and shared between CTC and PGP during
            the Study and Reporting Periods of the exclusive research
            opportunity, shall to the extent such Report, Data and Confidential
            Information directly relate to the CTC Compounds, be owned solely by
            CTC. Permitted uses and ownership of any Collaboration Compound or
            other jointly-developed intellectual property that may arise from
            any collaboration during the Study and Reporting Periods of the
            exclusive research opportunity are dealt with

CTC-PGP Research Agreement
29 June 2004

                                       5
<PAGE>

Confidential

            in Paragraphs 5.3 of this Agreement. Nothing in this Section 3.3
            shall be construed to reduce the rights and protections of PGP or
            relieve the obligations of CTC with respect to Confidential
            Information disclosed by PGP to CTC, pursuant to Section 4.

4   CONFIDENTIALITY

      4.1   In preparation of and during the course of the Project, it may be
            necessary for a Party to disclose Confidential Information to the
            other Party. The Parties agree that all Confidential Information
            disclosed to one Party by the other Party for the purposes of this
            Agreement (1) are to be received in strict confidence, (2) are to be
            used only for the purposes of this Agreement, and (3) are not to be
            disclosed by the recipient party, its agents, employees or assigns
            without the prior written consent of the other Party, except to the
            extent that such information, as established by relevant documentary
            evidence:

            4.1.1 was in the public domain at the time of disclosure;

            4.1.2 later became part of the public domain through no act or
                  omission of the recipient Party, its employees, agents,
                  successors or assigns;

            4.1.3 was lawfully disclosed to the recipient Party by a third party
                  having the right to disclose it;

            4.1.4 was already known by the recipient Party at the time of
                  disclosure;

            4.1.5 was independently developed by the recipient; or

            4.1.6 is required by law or regulation to be disclosed, provided
                  however, that the Party being obliged to disclose shall first
                  give the other Party written notice and adequate opportunity
                  to object to such order for disclosure or to request
                  confidential treatment.

      4.2   Confidential Information shall not be deemed to be available to the
            public or to be in the recipient's possession merely because it:

            4.2.1 includes information that falls within an area of general
                  knowledge available to the public or to the recipient (i.e.,
                  it does not include the specific information provided by the
                  other Party); or

            4.2.2 can be reconstructed in hindsight from a combination of
                  information from multiple sources that are available to the
                  public or to the recipient, if not one of those sources
                  actually taught or suggested the entire combination, together
                  with its meaning and importance.

      4.3   Each Party's obligation of confidence hereunder shall be fulfilled
            by using at least the same degree of care with the other Party's

CTC-PGP Research Agreement
29 June 2004

                                       6
<PAGE>

Confidential

            Confidential Information as it uses to protect its own Confidential
            Information. This obligation shall exist while this Agreement is in
            force and for a period of five (5) years thereafter.

5     INTELLECTUAL PROPERTY RIGHTS

      5.1   All rights to the Data and Confidential Information generated by PGP
            shall be exclusively owned by PGP.

      5.2   Notwithstanding 5.1, termination of the Agreement by PGP pursuant to
            6.6 or PGP decision to not negotiate or exercise a license agreement
            during the Option Period, then all rights to the Data will transfer
            to CTC.

      5.3   Subject to 5.2, CTC shall have the exclusive right to file patent
            applications on CTC Compounds utilizing the Data and all inventions
            made solely by CTC personnel. If CTC decides not to file a patent
            application on an invention made under the Study Plans, and PGP
            wishes to file a patent application on such invention, then PGP
            shall have the right to file such patent, after written approval is
            obtained from CTC, such approval not to be unreasonably withheld. In
            the latter case, PGP shall be the sole owner and beneficiary of such
            patent. Inventions created hereunder jointly by CTC and PGP, even if
            not solely related to CTC Compounds, shall be owned equally by CTC
            and PGP ("Joint Inventions"). If either CTC or PGP desires that a
            patent covering such Joint Inventions be obtained, they will
            determine and agree as to whether CTC or PGP will be responsible for
            preparation, filing and prosecution of patent applications; the
            other Party shall provide full cooperation for such efforts.
            Inventions made solely by PGP personnel and unrelated to CTC
            Compounds shall be owned by PGP.

6     TERM AND TERMINATION

      6.1   The Agreement will become effective on the Effective Date.

      6.2   The term of this Agreement shall be twelve (12) months from the
            receipt of CTC Compounds unless extended by mutual agreement of the
            Parties or terminated earlier in accordance with the provisions of
            this Agreement.

      6.3   Either Party ("the Terminating Party") shall be entitled to
            terminate this Agreement at any time by notice in writing to the
            other Party ("the Defaulting Party") if the Defaulting Party is in
            material breach of this Agreement which breach is irremediable or,
            if remediable, is not remedied by the defaulting Party within thirty
            (30) days of being requested to do so by the other.

            6.3.1 If the Defaulting Party is PGP and PGP fails to remedy the
                  material breach, then CTC shall own the Data and the exclusive
                  opportunity granted to PGP under Section 2.1 shall be
                  terminated.

CTC-PGP Research Agreement
29 June 2004

                                       7
<PAGE>

Confidential

            6.3.2 If the Defaulting Party is CTC and CTC fails to remedy the
                  material breach, then PGP shall own the Data.

      6.4   Either Party shall have the right to terminate the Agreement in case
            of bankruptcy or insolvency of the other Party.

      6.5   The Parties shall have the right to terminate the Agreement at any
            time by mutual written agreement of both Parties and subject to any
            terms herein which survive termination.

      6.6   PGP retains the right to terminate the Agreement at any time upon
            thirty (30) days written notice to CTC and subject to any terms
            herein which survive termination.

      6.7   Termination or expiration of this Agreement by a Party for any
            reason shall not affect the rights and obligations of the Parties
            accrued prior to the date of termination or expiration of this
            Agreement.

      6.8   No termination or expiration of this Agreement shall release the
            Parties from their rights and obligations under the Articles 4, 5,
            7, and 10.

7     PUBLIC ANNOUNCEMENTS

      7.1   Neither Party shall use the name of the other Party or of any member
            of the other Party's staff, in any publicity, advertising, news
            release or otherwise disclose the existence of this Agreement or the
            transactions contemplated hereby, unless required by law, without
            the prior written approval of an authorized representative of the
            other Party involved. Such written approval will not be unreasonably
            withheld or delayed.

8     NOTICES

      8.1   Any notices required to be given under this Agreement shall be in
            writing and shall be deemed duly served if hand delivered or sent by
            facsimile or by mail correctly addressed to the relevant Party's
            address as specified in Article 8.3. of this Agreement or at such
            other address as such Party may designate from time to time in
            writing in accordance with this clause. Any notice sent by mail
            shall be sent by registered mail and any notice sent by facsimile or
            telex shall be confirmed by registered mail.

      8.2   Any notice shall be deemed to have been served:

            8.2.1 if hand delivered, at the time of delivery;

            8.2.2 if sent by facsimile, eight (8) hours after the transmission
                  during normal business hours or, if transmission is not during
                  normal business hours, at the start of the normal business
                  hours on the next following day (exclusive of Saturdays,
                  Sundays and public holidays), but subject to production by the
                  sender of confirmation

CTC-PGP Research Agreement
29 June 2004

                                       8
<PAGE>

Confidential

                  from the transmitting facsimile machine that a satisfactory
                  transmission has been completed;

            8.2.3 if sent by mail, five (5) working days after mailing exclusive
                  of Saturdays, Sundays and public holidays.

NOTIFICATIONS SHALL BE SENT TO:

For CTC                                             For Globe Laboratories
       David Karp, MBA, CFA
       Chief Financial Officer                          Audrey Lew
       Chemokine Therapeutics Corp.                     Controller
       2386 East Mall                                   Globe Laboratories, Inc.
       Suite 208                                        2386 East Mall
       Vancouver, BC                                    Suite 208
       V6T 1Z3                                          Vancouver, BC
       Canada                                           V6T 1Z3
       Telephone: 604-822-3347                          Canada
       Facsimile: 604-822-0302                          Telephone: 604-822-0303
       Email: david@chemokine.net                       Facsimile: 604-822-0302

For PGP
       Don Lucas, Ph.D.
       Procter & Gamble Pharmaceuticals
       Health Care Research Center
       Mail Drop 1133
       8700 Mason-Montgomery Road
       Mason, Ohio,  USA  45040-9462
       Telephone: 513-622-3673
       Facsimile: 513-622-3699
       Email:  lucas.ds@pg.com

9     LIMITED WARRANTY

      9.1   Except as otherwise set forth herein, the Parties disclaim and
            exclude all other warranties or representations, express, implied or
            statutory, with respect to the CTC Compounds, or the Services
            provided for hereunder, including the implied warranties of
            merchantability, fitness for a particular purpose and
            non-infringement of a patent, trademark or other intellectual
            property right.

10    INDEMNIFICATION

      10.1  PGP shall indemnify, defend and hold harmless CTC and its directors,
            officers, employees, and agents, and their successors, heirs, and
            assigns (the "CTC Indemnitees") from and against liability, damage,
            loss or expense (including reasonable attorneys' fees and expenses
            of litigation) incurred by or imposed upon such CTC Indemnitees, or
            any of them, in connection with any third party claims, suits,
            actions, demands, or judgments, including, personal injury, death,
            damage to real or personal

CTC-PGP Research Agreement
29 June 2004

                                       9
<PAGE>

Confidential

            property, and product liability, to extent arising directly out of:
            (a) any actions or omissions of PGP under this Agreement; (b) any
            material breach of this Agreement by PGP; or (c) the negligence,
            gross negligence, or willful misconduct on the part of PGP; provided
            however, that PGP shall make no such indemnity to the extent such
            liability, damage, loss or expense is the result of CTC Indemnitees'
            negligence, gross negligence, or willful misconduct, during the Term
            of this Agreement.

      10.2  CTC shall indemnify, defend and hold harmless PGP and its directors,
            officers, employees, and agents, and their successors, heirs, and
            assigns (the "PGP Indemnitees") from and against liability, damage,
            loss or expense (including reasonable attorneys' fees and expenses
            of litigation) incurred by or imposed upon such PGP Indemnitees, or
            any of them, in connection with any third party claims, suits,
            actions, demands, or judgments, including, personal injury, death,
            damage to real or personal property, and product liability, to
            extent arising directly out of: (a) any actions or omissions of CTC
            under this Agreement; (b) any material breach of this Agreement by
            CTC; or (c) the negligence, gross negligence, or willful misconduct
            on the part of CTC; provided however, that CTC shall make no such
            indemnity to the extent such liability, damage, loss or expense is
            the result of PGP Indemnitees' negligence, gross negligence, or
            willful misconduct, during the Term of this Agreement.

11    MISCELLANEOUS

      11.1  This Agreement and its Appendices constitute the entire and only
            agreement between the Parties with respect to its subject matter as
            of the Effective Date and supersedes all prior agreements,
            negotiations, representations and proposals, written or oral,
            relating to its subject matter. No representation, undertaking or
            promise shall be taken to have been given or be implied from
            anything said or written in negotiations between the Parties prior
            to this Agreement except as expressly stated in this Agreement.

      11.2  If any provision, or part of any provision of this Agreement, or the
            Appendices hereto, is invalidated by operation of law or otherwise,
            that provision or part will to that extent be deemed omitted and the
            remainder of this Agreement, or applicable attachment, will remain
            in full force and effect. In place of any such invalid provision or
            part thereof, the Parties undertake to agree on a similar but valid
            provision the effect of which is as close as possible to that of the
            invalid provision or part thereof.

      11.3  No modification, amendment or waiver or any provision of this
            Agreement shall be effective unless in writing, specifically
            referring hereto and signed by both Parties.

CTC-PGP Research Agreement
29 June 2004

                                       10
<PAGE>

Confidential

      11.4  Failure of either Party to enforce at any time or for any period,
            any right under this Agreement, does not constitute, and shall not
            be construed as, a waiver of that right and shall not affect the
            right later to enforce that right or any other right term herein
            contained.

      11.5  Neither Party may assign, subcontract, or delegate its rights and
            obligations under this Agreement without the prior written consent
            of the other Party. This Agreement shall be binding upon the
            Parties, their successors and their permitted assigns.

      11.6  Headings are included herein for convenience only and shall not be
            used to construe this Agreement.

      11.7  Neither Party shall be held liable or responsible to the other Party
            nor deemed to have defaulted under or breached this Agreement for
            failure or delay in fulfilling or performing any term of this
            Agreement when such failure or delay is caused by or results from
            causes beyond the reasonable control of the affected Party which
            such Party could not reasonably be expected to have taken into
            account at the execution of this Agreement, including, without
            limitation, fires, floods, earthquakes, natural disasters,
            embargoes, war, acts of war (whether war is declared or not), acts
            of terrorism, insurrections, riots, civil commotions, strikes,
            lockouts or other labor disturbances, acts of God or acts, omissions
            or delays in acting by any governmental authority. Each Party shall
            keep the other Party informed of any delays of such type and shall
            use their reasonable efforts to minimize and mitigate the effect of
            such delays. However, once such cause has been corrected or removed,
            the Parties shall be held to their obligations hereunder with
            respect to such failed or delayed performance.

      11.8  Nothing in this Agreement and no action taken by the Parties
            pursuant to this Agreement shall constitute or be deemed to
            constitute a partnership between the Parties, or shall constitute
            either Party as the agent, employee or representative of the other.

      11.9  This Agreement may be executed in one or more counterparts and such
            counterparts shall each be considered originals, and shall together
            constitute one document.

      11.10 All Parties must comply with all applicable national, state and
            local laws and regulations in connection with its activities
            pursuant to this Agreement.

      11.11 This Agreement is governed in accordance with the laws of the United
            States of America and of the State of Ohio.

CTC-PGP Research Agreement
29 June 2004

                                       11
<PAGE>

Confidential

IN WITNESS WHEREOF the Parties have executed this Agreement as for the date last
set forth below:

PROCTER & GAMBLE PHARMACEUTICALS INC.       CHEMOKINE THERAPEUTICS CORP.

/s/ Larry Games                             /s/ Hassan Salari
--------------------------------------      ------------------------------------
Name:  Larry M. Games, Ph.D.                Name:  Hassan Salari, Ph.D.

Title: Vice President                       Title: Chairman & CEO
       Global Pharmaceuticals

Date:                                       Date:
      --------------------------------            ------------------------------

CTC-PGP Research Agreement
29 June 2004

                                       12
<PAGE>

Confidential

APPENDIX A

                                  CTC COMPOUNDS

      1) CTCE-0021 [***]*

Structure:

      [***]*

      2) CTCE-0029 [***]*

 Structure:

      [***]*

      3) CTCE-0448 [***]*

Structure:

      [***]*

      4) CTCE-02111 [***]*

Structure:

      [***]*

      5) CTCE-02112 [***]*

Structure:

      [***]*

CTC-PGP Research Agreement
29 June 2004

* PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
  TREATMENT AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                       13
<PAGE>

Confidential

APPENDIX B

                                   STUDY PLANS

      [***]*

CTC-PGP Research Agreement
29 June 2004

* PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
  TREATMENT AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                       14
<PAGE>

Confidential

      APPENDIX C

                               HEADS OF AGREEMENT

    Chemokine Therapeutics, Corp. and Procter & Gamble Pharmaceuticals, Inc.
              Heads of Agreement for License and Commercialization

Chemokine Therapeutics, Corp. (hereafter CTC) with its offices in Vancouver,
British Columbia, Canada and Procter & Gamble Pharmaceuticals, Inc. (hereafter
PGP) with its offices in Mason, Ohio, propose entering into a collaboration to
validate cardiovascular targets and active molecules that therapeutically affect
those targets. Within the collaboration, PGP will have an exclusive option to
take an exclusive license to further develop one (1) CTC compound and up to four
(4) back-up compounds for Further Development and Commercialization with the
goal for Commercialization of one compound. Commercialization of a second
compound by PGP will require a new and separate agreement.

Therefore, the Parties agree to the following terms as a basis for a license
agreement should PGP decide to exercise its option.

FIELD                      The Field shall be the development of therapeutic
                           drugs for vascular and cardiovascular disease, and
                           cardiac muscle regeneration including
                           neovascularization.

TERM                       The Term shall be the latter of expiration of
                           regulatory exclusivity in a Major Market Territory
                           covering a marketed Compound or expiration of patent
                           rights on a country-by-country basis; or early
                           termination as described in the Collaboration
                           Agreement.

TERRITORY                  The Territory shall be any territory worldwide.

MAJOR MARKET TERRITORY     Major Market Territory includes the European Union
                           countries or any of the following countries: United
                           States, Canada, United Kingdom, France,
                           Germany, Italy, Spain, Australia, Brazil or Japan.

TECHNOLOGY                 The Technology shall be the assets provided by each
                           of the Parties to the collaboration and the results
                           of the work done by the Parties in the
                           collaboration as proposed in the work plan.

CTC COMPOUND               A CTC Compound is a compound that is owned by CTC, or
                           CTC has exclusive worldwide license to the compound,
                           and is covered by the Agreement

COLLABORATION COMPOUND     A Collaboration Compound is a compound not mentioned
                           in CTC patents to date, and will be developed jointly
                           during the Research Collaboration and is owned
                           jointly by CTC and PGP

CTC-PGP Research Agreement
29 June 2004

                                       15
<PAGE>

Confidential

CURRENCY                   All currency quotations are in United States of
                           America (US) dollars (US$). "MM" is defined as US
                           million dollars (US$).

FURTHER DEVELOPMENT        Preclinical research activities conducted in
                           preparation for filing of an IND

COMMERCIALIZATION          Filing of a New Drug Application (NDA) for Regulatory
                           Approval by the FDA following the completion of
                           clinical trials.

LICENSE                    CTC will grant to PGP an exclusive License in the
                           Territory to the Technology for CTC Compounds during
                           the Term. CTC agrees that they will not compete or
                           enter into an agreement with a third party in the
                           Field and during the Term.

PATENT FILING              PGP agrees to pay CTC all costs associated with
                           additional patent filings, including, but not limited
                           to, filings on the five compounds for therapeutic
                           angiogenesis. PGP may at its option, choose to
                           participate in writing the patents and defining the
                           claims.

R&D SUPPORT                PGP will pay the direct and indirect costs for two
                           (2) full-time equivalent (FTE) CTC employees at an
                           agreed upon rate of [***]* ($[***]*) dollars per FTE
                           employee per annum from the date of execution of the
                           option through filing of the IND.

LICENSE FEE                Upon execution of an Option for Compounds provided by
                           the Collaboration Agreement, PGP will pay to CTC a
                           License Fee in the amount of five hundred thousand
                           ($[***]*) dollars.

MILESTONES                 PGP will pay to CTC Milestones for the following
                           events in the development of a CTC Compound:

                           Filing of an IND or equivalent                $[***]*
                           Initiation of Phase II Study                  $[***]*
                           Initiation of Phase III Study                 $[***]*
                           Approval of NDA                               $[***]*

                           PGP will pay to CTC Milestones for the following
                           events in the development of a Collaboration
                           Compound:

                           Filing of an IND or equivalent                $[***]*
                           Initiation of Phase II Study                  $[***]*
                           Initiation of Phase III Study                 $[***]*
                           Approval of NDA                               $[***]*

CTC-PGP Research Agreement
29 June 2004

* PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
  TREATMENT AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                       16
<PAGE>

Confidential

TIERED ROYALTIES    PGP will pay royalties to CTC for CTC Compounds according
                    to the following schedule for net sales in the Territory.

                    Net annual sales < $[***]* MM                        [***]*%

                    Net annual sales between $[***]*MM and $[***]*MM     [***]*%

                    Net annual sales between $[***]*MM and $[***]*MM     [***]*%

                    Net annual sales between $[***]*MM and $[***]*MM     [***]*%

                    Net annual sales > $[***]*MM                         [***]*%

                    PGP will pay royalties to CTC for Collaboration
                    Compounds according to the following schedule for net
                    sales in the Territory.

                    Net annual sales < $[***]*MM                         [***]*%

                    Net annual sales between $[***]*MM and $[***]*MM     [***]*%

                    Net annual sales between $[***]*MM and $[***]*MM     [***]*%

                    Net annual sales between $[***]*MM and $[***]*MM     [***]*%

                    Net annual sales > $[***]*MM                         [***]*%

THE FOLLOWING IS PROVIDED FOR PURPOSES OF A TIERED ROYALTY EXAMPLE ONLY. If Net
Annual Sales of a Collaboration Compound are $[***]*, then the royalty on those
sales would be $[***]* ($[***]* X [***]*%) plus $[***]* ($[***]* X [***]*%) for
a total annual royalty of $[***]*.

PROCTER & GAMBLE PHARMACEUTICALS INC.       CHEMOKINE THERAPEUTICS CORP.

____________________________________        ____________________________________
Name:  Mark Collar                          Name:  Hassan Salari, Ph.D.

Title: President                            Title: Chairman & CEO
       Global Pharmaceuticals

Date: ______________________________        Date:_______________________________

CTC-PGP Research Agreement
29 June 2004

* PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
  TREATMENT AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                       17<PAGE>

                                                                   EXHIBIT 10.15

                                 LEASE AGREEMENT
                                 ---------------

LANDLORD:                  SALARI ENTERPRISE LTD.

ADDRESS OF PREMISE:        1080 Howe Street, Suite 501, Vancouver, BC V6Z 1P5

TENANT:                    CHEMOKINE THERAPEUTICS CORP.

TENANT'S ADDRESS:          2386 East Mall (UBC), Unit 208, Vancouver, BC V6T 1Z3

TERM:                      Five (5) years.

COMMENCEMENT DATE:         January 01, 2003

BASIC RENT:                $2,000 per month, plus GST ($2,000 + $140; total
                           $2,140)

SCOPE OF ACTIVITY:         Biopharmaceutical business activity

PARKING PERMIT:            One (1) parking included in the price, (slot #11)

DEPOSIT:                   One (1) month; $2,070

LANDLORD'S WORK:           Tenant is responsible for all the improvement costs.

RENEWAL TERM:              One (1) Option to Renew for a term of 1 year.

EARLY TERMINATION;         Tenant has the right to terminate the Lease at any
time prior to the end of the Term. However, Tenant is responsible for the full
payment of the remaining Lease from the date of early termination notice to the
end of the 5-year term.

The parties in consideration of the covenants and agreements in this Lease
contained, covenant and agree each with the other that the terms herein shall
form the Lease Agreement, and the parties shall be bound by the same. The Laws
of the Province of British Columbia govern this Agreement.

IN WITNESS WHEREOF the Landlords, the Tenant have executed this Lease as of the
01st day of January 2003.

Landlord:                                          Tenant:
SALARI ENTERPRISES LTD.                            CHEMOKINE THERAPEUTICS CORP.

/s/ Hassan Salari                                  /s/ Walter Korz

Authorized Signatory                               Authorized Signatory

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00072-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00072-of-00352.parquet"}]]